Loring Wolcott & Coolidge Fiduciary Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-73	Closed	-$7K	–	648
2016 Q2	$7K	Hold	73	–	–	﹤0.01%	573
2016 Q1	$12K	Hold	73	–	–	﹤0.01%	525
2015 Q4	$24K	Hold	73	–	–	﹤0.01%	500
2015 Q3	$29K	Hold	73	–	–	﹤0.01%	469
2015 Q2	$29K	Buy	+73	New	+$31K	﹤0.01%	469

Other funds holding LUMO

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's LUMO Position: Q3 2016 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2016, closing a stake of 73 shares — an estimated $7K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in LUMO in Q2 2015 and held it in 5 quarters. The position peaked at $29K in Q3 2015. 104 funds tracked by Wall St. Rank hold LUMO as of Q3 2016.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 73 Lumos Pharma, Inc. Common Stock shares in Q3 2016, an estimated $7K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2015 and held it in 5 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's Lumos Pharma, Inc. Common Stock position peaked at $29K in Q3 2015.
104 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2016.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q3 2016, filed 1 Nov 2016.